Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.41 |
| ▸ | QDPR | P09417 | 2/20 | 0.41 |
| ▸ | ACMSD | Q8TDX5 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
| ▸ | DHODH | Q02127 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29924409 | 1.00 | MAOB (0.41) | MAOBQDPRACMSDMAOACES2 | |
| SCHEMBL18559476 | 0.89 | ESR2 (0.42) | MAOBQDPRACMSDMAOA | |
| SCHEMBL28400897 | 0.89 | PRKAB2 (0.43) | MAOB | |
| SCHEMBL10783589 | 0.87 | CYP2C9 (0.53) | MAOBMAOA | |
| SCHEMBL29210599 | 0.85 | MAOB (0.38) | MAOBMAOACES2CES1 | |
| SCHEMBL10951397 | 0.85 | CYP2C9 (0.45) | MAOB | |
| SCHEMBL10780906 | 0.84 | CYP2C9 (0.44) | — | |
| SCHEMBL10408450 | 0.84 | CYP2C9 (0.50) | MAOBMAOA | |
| SCHEMBL10408453 | 0.84 | CYP2C9 (0.50) | MAOBMAOA | |
| SCHEMBL10408452 | 0.84 | CYP2C9 (0.50) | MAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353858-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | BEONE MEDICINES I GMBH (CH) | 2025-11-20 | — | — | US | disclosed |
| US-20240368177-A1 | 5-AMINO-6,8-DIHYDRO-1H-FURO[3,4-d]PYRROLO[3,2-b]PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 | BEIGENE SWITZERLAND GMBH (CH) | 2024-11-07 | — | — | US | disclosed |
| CN-117177970-A | Polycyclic derivative regulator, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2023-12-05 | — | — | CN | disclosed |
| EP-3204376-B1 | INDOLINONE COMPOUNDS AND USES THEREOF | ONCTERNAL THERAPEUTICS INC (US) | 2023-04-19 | — | — | EP | disclosed |
| US-20220288023-A1 | INDOLINONE COMPOUNDS AND USES THEREOF | GEORGETOWN UNIVERSITY | 2022-09-15 | — | — | US | disclosed |
| EP-3285581-B1 | PYRAZOLYL PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME (US) | 2021-08-11 | — | — | EP | disclosed |
| WO-2020109224-A1 | FURTHER HETEROAROMATIC COMPOUNDS HAVING ACTIVITY AGAINST RSV | Janssen Sciences Ireland Unlimited Company (IE) | 2020-06-04 | — | — | WO | disclosed |
| US-10287269-B2 | Pyrazolyl pyrimidinone compounds as PDE2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-05-14 | — | — | US | disclosed |
| US-20180256546-A1 | INDOLINONE COMPOUNDS AND USES THEREOF | GEORGETOWN UNIVERSITY | 2018-09-13 | — | — | US | disclosed |
| US-9987251-B2 | Indolinone compounds and uses thereof | Oncternal Therapeutics, Inc. (US) | 2018-06-05 | — | — | US | disclosed |
| US-20170066720-A1 | INDOLINONE COMPOUNDS AND USES THEREOF | GEORGETOWN UNIVERSITY | 2017-03-09 | — | — | US | disclosed |
| US-20170066720-A1 | INDOLINONE COMPOUNDS AND USES THEREOF | GEORGETOWN UNIVERSITY | 2017-03-09 | — | — | US | disclosed |
| US-20170066720-A1 | INDOLINONE COMPOUNDS AND USES THEREOF | GEORGETOWN UNIVERSITY | 2017-03-09 | — | — | US | disclosed |
| US-20170065559-A1 | INDOLINONE COMPOUNDS AND USES THEREOF | GEORGETOWN UNIVERSITY | 2017-03-09 | — | — | US | disclosed |
| US-20170065559-A1 | INDOLINONE COMPOUNDS AND USES THEREOF | GEORGETOWN UNIVERSITY | 2017-03-09 | — | — | US | disclosed |
| WO-2016154081-A1 | PYRAZOLYL PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-09-29 | — | — | WO | disclosed |
| WO-2016057698-A1 | INDOLINONE COMPOUNDS AND USES THEREOF | Tokalas, Inc. (US) | 2016-04-14 | — | — | WO | disclosed |
| US-20160102055-A1 | INDOLINONE COMPOUNDS AND USES THEREOF | GEORGETOWN UNIVERSITY | 2016-04-14 | — | — | US | disclosed |
| US-20160102055-A1 | INDOLINONE COMPOUNDS AND USES THEREOF | GEORGETOWN UNIVERSITY | 2016-04-14 | — | — | US | disclosed |
| US-20160102055-A1 | INDOLINONE COMPOUNDS AND USES THEREOF | GEORGETOWN UNIVERSITY | 2016-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066720-A1 | INDOLINONE COMPOUNDS AND USES THEREOF | FLI1, EWSR1, IKZF1 | MAOB 2621/4885QDPR 4499/4885ACMSD 4850/4885 |
| US-20160102055-A1 | INDOLINONE COMPOUNDS AND USES THEREOF | FLI1, EWSR1, IKZF1 | MAOB 2621/4885QDPR 4499/4885ACMSD 4850/4885 |
| US-20250353858-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | DGKG, DGKK, DGKA | MAOB 3122/4885QDPR 2768/4885ACMSD 3047/4885 |
| US-20220288023-A1 | INDOLINONE COMPOUNDS AND USES THEREOF | FLI1, EWSR1, IKZF1 | MAOB 2621/4885QDPR 4499/4885ACMSD 4850/4885 |
| US-20170065559-A1 | INDOLINONE COMPOUNDS AND USES THEREOF | FLI1, EWSR1, IKZF1 | MAOB 2621/4885QDPR 4499/4885ACMSD 4850/4885 |
| US-20180256546-A1 | INDOLINONE COMPOUNDS AND USES THEREOF | FLI1, EWSR1, IKZF1 | MAOB 2621/4885QDPR 4499/4885ACMSD 4850/4885 |
| US-20240368177-A1 | 5-AMINO-6,8-DIHYDRO-1H-FURO[3,4-d]PYRROLO[3,2-b]PYRIDINE-2-CARBOXAMIDE DERIVATIVES AS MTA-COOPERATIVE INHIBITORS OF PRMT5 | PRMT5, PRMT6, PRMT1 | MAOB 3356/4885QDPR 1881/4885ACMSD 3514/4885 |
| US-10287269-B2 | Pyrazolyl pyrimidinone compounds as PDE2 inhibitors | PDE2A, PDE12, PDE5A | MAOB 149/4885QDPR 26/4885ACMSD 3499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.